British Journal of Cancer · 2013 · 99 citations · 34 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyHepatocellular Carcinoma PharmacotherapyOncology PharmacologyTyrosine Kinase InhibitorsApoptosis InductionCaspase-mediated ApoptosisMitochondrial Cell Death PathwaysOxidative Stress In CancerRaf SignalingReactive Oxygen Species GenerationReceptor Tyrosine Kinase ActivationSorafenib Therapy
BACKGROUND: Sorafenib is a potent inhibitor against Raf kinase and several receptor tyrosine kinases that has been approved for the clinical treatment of advanced renal and liver cancer. Combining sorafenib with other agents has been shown to improve its antitumour efficacy by not only reducing the toxic side effects but also preventing primary and acquired resistance to sorafenib. We have previously observed that tetrandrine exhibits potent antitumour effects in human hepatocellular carcinoma. In this study, we investigated the synergistic antitumour activity of sorafenib in combination with tetrandrine. METHODS: This was a two-part investigation that included the in vitro effects of sorafenib in combination with tetrandrine on cancer cells and the in vivo antitumour efficacy of this drug combination on tumour xenografts in nude mice. RESULTS: Combined treatment showed a good synergistic antitumour effect yet spared non-tumourigenic cells. The potential molecular mechanism may be mainly that it activated mitochondrial death pathway and induced caspase-dependent apoptosis in the cancer cells. Accumulation of intracellular reactive oxygen species (ROS) and subsequent activation of Akt may also be involved in apoptosis induction. CONCLUSION: The antitumour activity of sorafenib plus tetrandrine may be attributed to the induction of the intrinsic apoptosis pathway through ROS/Akt signaling. This finding provides a novel approach that may broaden the clinical application of sorafenib.
34
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Tim Eisen, T. Ahmad, Keith T. Flaherty et al. · British Journal of Cancer · 2006 · 636 citations · Full text
Medicine, Oncology, Pharmacology +15
ROS implication in a new antitumor strategy based on non‐thermal plasma
Marc Vandamme, Éric Robert, Stéphanie Lerondel et al. · International Journal of Cancer · 2011 · 595 citations · Full text
Medicine, Cancer Biology, Oncology +14